Enovis announces Davide Visentin as new President of International Surgical, effective March 1, 2025, succeeding Dr. Benjamin Reinmann.
Quiver AI Summary
Enovis™, a global medical technology innovator based in the United States, has announced that Davide Visentin will take over as President of Enovis International Surgical, effective March 1, 2025, succeeding Dr. Benjamin Reinmann. Visentin brings over 20 years of healthcare experience, previously serving as Vice President and General Manager at BD, where he led a large team and successfully gained market share. He has also held leadership roles at Stryker and Johnson & Johnson. Louie Vogt, Group President of Enovis’ Reconstructive Business Group, praised Reinmann's contributions and expressed enthusiasm for Visentin’s dynamic leadership and orthopedic passion, emphasizing the company's commitment to growth and innovation to improve patient outcomes. Visentin will primarily be based in Italy and Switzerland, furthering Enovis' goal of becoming a global leader in orthopedics.
Potential Positives
- Davide Visentin's appointment as President of Enovis International Surgical brings over 20 years of healthcare experience and a proven track record in growing businesses in the MedTech sector.
- The transition follows a period of successful leadership by Dr. Benjamin Reinmann, signaling continuity amidst change and the potential for further growth in the International Surgical Business.
- Visentin's previous roles, including management of a large team and market share gains in competitive environments, position him well to advance Enovis' strategic goals.
- Enovis is confident in gaining market share and driving growth through innovation, highlighting a strong commitment to improving patient outcomes and operational efficiency.
Potential Negatives
- The transition of leadership from Dr. Benjamin Reinmann to Davide Visentin may create uncertainty among employees and stakeholders regarding the future direction of the company.
- The departure of a long-serving leader raises questions about potential changes in company strategy and culture, which could impact employee morale and customer confidence.
FAQ
Who will succeed Dr. Benjamin Reinmann at Enovis?
Davide Visentin will succeed Dr. Benjamin Reinmann as President of Enovis International Surgical effective March 1, 2025.
What is Davide Visentin's background in healthcare?
Visentin has over 20 years of experience in MedTech, previously leading businesses at BD, Stryker, and Johnson & Johnson.
Where will Davide Visentin primarily work?
Visentin will primarily work in Villanova, Italy, and Bettlach, Switzerland.
What did Louie Vogt say about Davide Visentin?
Vogt described Visentin as a dynamic leader with a proven track record in business growth and a passion for orthopedics.
What goals does Enovis have for its International Surgical Business?
Enovis aims to become a global orthopedic leader by advancing strategic goals, gaining market share, and driving innovation for better patient outcomes.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$ENOV Hedge Fund Activity
We have seen 160 institutional investors add shares of $ENOV stock to their portfolio, and 115 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- THRIVENT FINANCIAL FOR LUTHERANS removed 1,579,438 shares (-86.8%) from their portfolio in Q3 2024, for an estimated $67,994,805
- RIVER ROAD ASSET MANAGEMENT, LLC added 1,192,595 shares (+inf%) to their portfolio in Q3 2024, for an estimated $51,341,214
- AMERICAN CENTURY COMPANIES INC added 817,676 shares (+54.1%) to their portfolio in Q3 2024, for an estimated $35,200,951
- SELECT EQUITY GROUP, L.P. removed 542,565 shares (-97.5%) from their portfolio in Q3 2024, for an estimated $23,357,423
- PRINCIPAL FINANCIAL GROUP INC removed 492,199 shares (-79.1%) from their portfolio in Q3 2024, for an estimated $21,189,166
- CHANNING CAPITAL MANAGEMENT, LLC removed 450,392 shares (-26.3%) from their portfolio in Q3 2024, for an estimated $19,389,375
- ROYCE & ASSOCIATES LP added 346,317 shares (+16.8%) to their portfolio in Q3 2024, for an estimated $14,908,946
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
Wilmington, DE, Jan. 17, 2025 (GLOBE NEWSWIRE) -- Enovis™, a global medical technology innovator headquartered in the United States, announced recently that Davide Visentin will succeed Dr. Benjamin Reinmann as President of Enovis International Surgical, effective March 1, 2025.
Visentin is a successful MedTech executive who comes to Enovis with more than 20 years of healthcare experience. Most recently, he was the Vice President and General Manager of the Integrated Diagnostic Solutions Business Unit for BD, where he managed more than 700 employees across 50 countries and gained market share in a very competitive market. Prior to BD, Visentin served as Vice President and General Manager of Europe for Stryker’s Joint Replacement and Robotic Division, and Vice President, EMEA, for Johnson & Johnson Depuy Synthes.
“Under Benjamin Reinmann’s leadership, Enovis has created a world-class International Surgical Business. We sincerely thank Benjamin for his numerous contributions to the growth and success of both Enovis and Mathys, and especially throughout the critical integration of legacy companies Mathys and LimaCorporate,” said Louie Vogt, Group President of Enovis’ Reconstructive Business Group. “We are very excited to welcome Davide to Enovis. He is a dynamic leader with a strong track record of successfully growing businesses, a true passion for orthopedics, and the experience and playbook to take our business to the next level.”
Visentin has a degree in Computer Science from the University of Milan. He will primarily spend his time in Villanova, Italy, and Bettlach, Switzerland.
“We continue to make great progress with building and growing our International Surgical Business into a global orthopedics leader that is thriving because of our team’s commitment to excellence and to going above and beyond every day to create better together,” added Vogt. “The momentum we created in 2024 puts us in a strong position to advance our strategic goals, continue gaining market share and drive growth through innovation, all with the ultimate goal of improving patient outcomes.”
About Enovis
Enovis™ (NYSE: ENOV) is a global medical technology innovator dedicated to improving lives by developing clinically differentiated solutions that enhance patient outcomes and restore motion for life. We partner with the brightest minds in health to advance care that is smarter, personalized, and more effective, while improving operational efficiency for surgeons and clinicians around the world. Enovis solutions impact the well-being of millions of patients wherever they are on their pathway to health. Learn more about Enovis at
www.enovis.com
.
Media Contact
Lee Griffin
Vice President, Global Marketing Communications & Digital, Enovis
+1 (469) 794-9760
[email protected]
